RTP Mobile Logo
Oncology Today with Dr Neil Love: Management of Non-Small Cell Lung Cancer with ALK and ROS1 Rearrangements (Video Program)
Released November 2020

Featuring an interview with Dr D Ross Camidge. (Video Program)

CE Disclosures and Faculty Information

    This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of lung cancer.


    • Appraise the efficacy and safety of approved and investigational ALK inhibitors, and determine how these agents can be integrated into the protocol and nonresearch care of patients with NSCLC with ALK rearrangements.
    • Describe mechanisms of tumor resistance to ALK inhibitors, and discern how available and investigational therapies can be optimally employed in current and future clinical practice for patients with advanced NSCLC with ALK rearrangements.
    • Consider the mechanism of action of, available data with and FDA approval of entrectinib for patients with NSCLC with ROS1 alterations, and discern how this agent can be appropriately and safely integrated into routine clinical care.
    • Develop an optimal approach to the management of NSCLC in patients with ALK or ROS1 rearrangements and CNS metastases, considering the implications of symptomatology, number of lesions and other factors.
    • Recall ongoing clinical trials evaluating novel therapeutic approaches for NSCLC with ALK or ROS1 rearrangements, and refer appropriate patients for participation.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CME credit is no longer available for this issue

    This CME activity consists of a video component.
    CME credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and his spouse/partner) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    D Ross Camidge, MD, PhD
    Professor of Medicine/Oncology
    Joyce Zeff Chair in Lung Cancer Research
    Director of Thoracic Oncology
    University of Colorado, Anschutz Medical Campus
    Denver, Colorado

    Company Sponsored Trials at Institution (PI Roles): AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, GlaxoSmithKline, Hansoh Pharma, Inhibrx, Karyopharm Therapeutics, Lycera, Merck, Pfizer Inc, Phosplatin Therapeutics, PsiOxus Therapeutics, Rain Therapeutics, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Symphogen A/S, Takeda Oncology; Data Safety Monitoring Board: AstraZeneca Pharmaceuticals LP, HiberCell; ILD Adjudication Committee: Bristol-Myers Squibb Company, Daiichi Sankyo Inc; Scientific Advisory Board: Amgen Inc, Anchiano Therapeutics, GlaxoSmithKline, Helsinn Healthcare SA, Janssen Biotech Inc, Lilly, OnKure, Pfizer Inc, Qilu Pharmaceutical Co Ltd, Roche Laboratories Inc, Sanofi Genzyme, Seagen Inc, Takeda Oncology; Scientific Review Committee: Apollomics Inc, EMD Serono Inc, Sunovion Respiratory Development Inc.

    EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seagen Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Verastem Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

    This activity is supported by an educational grant from Takeda Oncology.

    Release date: November 2020
    Expiration date: November 2021

Acknowledge and close

Watch video
(WIFI is recommended for best performance):